Sugi Predict

Sugi Predict / Compounds / SCHEMBL1077002

SCHEMBL1077002

SCHEMBL1077002

CCc1cccn1-c1c(C#N)c2ccccc2n1-c1ccc(O)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 8/20 0.38
▸ L3MBTL1 Q9Y468 5/20 0.38
▸ LMNA P02545 5/20 0.38
▸ MEN1 O00255 4/20 0.38
▸ KMT2A Q03164 4/20 0.38
▸ GAA P10253 3/20 0.38
▸ KDM4E B2RXH2 3/20 0.38
▸ MAPT P10636 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ NCOA3 Q9Y6Q9 1/20 0.38
▸ EGFR P00533 1/20 0.36
▸ SRC P12931 1/20 0.36
▸ MAPK1 P28482 4/20 0.35
▸ STAT3 P40763 1/20 0.35
▸ TDP1 Q9NUW8 2/20 0.35
▸ GLA P06280 2/20 0.34
▸ TSHR P16473 2/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1077453 0.86 ALDH1A1 (0.41) ALDH1A1L3MBTL1LMNAMEN1KMT2A
SCHEMBL2310990 0.85 ALDH1A1 (0.33) ALDH1A1L3MBTL1LMNAMEN1KMT2A
SCHEMBL1075953 0.83 ALDH1A1 (0.41) ALDH1A1L3MBTL1LMNAMEN1KMT2A
SCHEMBL1077176 0.81 EGFR (0.38) ALDH1A1L3MBTL1LMNAMEN1KMT2A
SCHEMBL1078139 0.80 ALDH1A1 (0.33) ALDH1A1L3MBTL1LMNAMEN1KMT2A
SCHEMBL1039962 0.78 KDM4E (0.48) ALDH1A1L3MBTL1LMNAMEN1KMT2A
SCHEMBL1083675 0.78 USP14 (0.33) ALDH1A1LMNAMEN1KMT2AKDM4E
SCHEMBL1083670 0.78 USP14 (0.33) ALDH1A1LMNAMEN1KMT2AKDM4E
SCHEMBL1083672 0.77 USP14 (0.33) ALDH1A1LMNAKDM4EMAPK1GLA
SCHEMBL1077332 0.75 CYP11B2 (0.39) ALDH1A1L3MBTL1LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2276732-B1 NOVEL ESTROGEN RECEPTOR LIGANDS KAROBIO AB (SE) 2015-05-20 — — EP claimed
US-8653072-B2 Estrogen receptor ligands KARO BIO AB (SE) 2014-02-18 — — US claimed
US-20130131061-A1 Novel Estrogen Receptor Ligands KARO BIO AB (SE) 2013-05-23 — — US claimed
US-8367665-B2 Estrogen receptor ligands KARO BIO AB (SE) 2013-02-05 — — US claimed
US-20110190294-A1 NOVEL ESTROGEN RECEPTOR LIGANDS OASMIA PHARMACEUTICAL AB (SE) 2011-08-04 — — US claimed
CN-102066323-A Novel estrogen receptor ligands KAROBIO AB 2011-05-18 — — CN claimed
EP-3782616-B1 ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES UNIV CALIFORNIA (US) 2023-11-01 — — EP disclosed
US-11628146-B2 Estrogen receptor ligand treatment for neurodegenerative diseases THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-04-18 — — US disclosed
EP-3782616-A1 ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES The Regents of The University of California (US) 2021-02-24 — — EP disclosed
US-10758496-B2 Estrogen receptor ligand treatment for neurodegenerative diseases THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2020-09-01 — — US disclosed
EP-3189026-B1 ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES UNIV CALIFORNIA (US) 2020-07-22 — — EP disclosed
US-20170304216-A1 ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2017-10-26 — — US disclosed
WO-2017031276-A1 METHODS OF PROVIDING NEUROPROTECTIVE THERAPY RELATED TO ADMINISTERING AN ESTROGEN RECEPTOR BETA LIGAND THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-02-23 — — WO disclosed
EP-2276732-B1 NOVEL ESTROGEN RECEPTOR LIGANDS KAROBIO AB (SE) 2015-05-20 — — EP disclosed
US-8653072-B2 Estrogen receptor ligands KARO BIO AB (SE) 2014-02-18 — — US disclosed
US-20130131061-A1 Novel Estrogen Receptor Ligands KARO BIO AB (SE) 2013-05-23 — — US disclosed
US-8367665-B2 Estrogen receptor ligands KARO BIO AB (SE) 2013-02-05 — — US disclosed
US-20110190294-A1 NOVEL ESTROGEN RECEPTOR LIGANDS OASMIA PHARMACEUTICAL AB (SE) 2011-08-04 — — US disclosed
EP-2276732-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2011-01-26 — — EP disclosed
WO-2009127686-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2009-10-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170304216-A1 ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES ESR2, ESRRG, ESR1 ALDH1A1 2803/4885L3MBTL1 3715/4885LMNA 3275/4885
US-11628146-B2 Estrogen receptor ligand treatment for neurodegenerative diseases ESR2, ESRRG, ESR1 ALDH1A1 2803/4885L3MBTL1 3715/4885LMNA 3275/4885
US-20130131061-A1 Novel Estrogen Receptor Ligands ESR1, GPER1, ESRRA ALDH1A1 1765/4885L3MBTL1 2731/4885LMNA 3927/4885
US-20110190294-A1 NOVEL ESTROGEN RECEPTOR LIGANDS ESR1, GPER1, ESRRA ALDH1A1 1909/4885L3MBTL1 2834/4885LMNA 3887/4885
US-10758496-B2 Estrogen receptor ligand treatment for neurodegenerative diseases ESR2, ESRRG, ESR1 ALDH1A1 2803/4885L3MBTL1 3715/4885LMNA 3275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.